IDXX Stock Recent News

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.

Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices.

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million.

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago.

IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to the vet clinic.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. “IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally,” said Jay Mazelsky, President and Chief Executive Officer. "The Company is on the front end of a new wave of major innovation. In Q4, we began shipping the IDEXX inVue Dx™ Cellular Analyzer, our transformational sli.

IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.

IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2024 Earnings Snapshot through a link on.